文献速递心力衰竭与心肌病冠心病

供体动脉粥样硬化风险与冠状动脉造影对心脏移植移植物存活的影响

Heart transplantation allograft survival: donor atherosclerotic disease risk vs coronary angiography.
PubMed 文献 · Eur Heart J · 2026-08-20

基于UNOS数据库2018至2023年5152例成人心脏移植受者,评估供体10年ASCVD风险(≤5% vs >5%)与冠脉造影对移植后4年死亡或移植物衰竭复合终点的预测价值。结果显示供体ASCVD风险>5%且行造影者风险显著升高(aHR 1.30),而低风险供体行造影未见获益,提示ASCVD风险分层可能优于造影作为初始筛选步骤。

要点

  • 供体ASCVD风险>5%且行造影者4年内死亡或移植物衰竭风险显著升高(aHR 1.30)。
  • ASCVD风险分层可能比常规冠脉造影更适合作为供体心脏初始筛选工具。

核心结论

  • 供体估计ASCVD风险>5%独立预测更差的移植结局,而低风险供体常规冠脉造影并未改善结局。
  • 基于ASCVD的风险分层可能比造影更适合作为供体心脏选择的初始步骤。

研究设计与样本

  • 纳入标准:供体年龄>40岁,或>30岁且合并糖尿病、高血压或吸烟。
  • 共纳入5152例受者,采用多变量Cox回归评估移植后4年内死亡或移植物衰竭复合终点。

主要发现

  • 86.1%的受者接受供体ASCVD风险≤5%的心脏;ASCVD≤5%供体中76.1%行造影,ASCVD>5%供体中92.9%行造影。
  • ASCVD>5%且行造影组(n=663)的aHR为1.30(95%CI 1.05-1.60)。
  • 限定于符合当前造影指南标准的供体时,结果一致。

关键数值与推荐

  • 指南推荐对冠心病风险增加的供体(年龄>45岁、糖尿病、吸烟或药物使用)行冠状动脉造影。
  • 本研究以供体估计10年ASCVD风险≤5% vs >5%进行分层。

临床怎么用

  • 在供体心脏评估中,可优先使用估计10年ASCVD风险进行风险分层,而非对所有低风险供体常规行冠脉造影。
  • 对于ASCVD风险>5%的供体,即使行造影,移植后结局仍较差,需谨慎评估。

局限性

  • 回顾性观察性研究,可能存在未测量混杂。
  • ASCVD>5%且未行造影组样本量小(n=51),置信区间宽。
  • 仅纳入供体年龄>40岁或>30岁合并危险因素者,结论外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Guidelines recommend coronary angiography in heart donors at increased risk of coronary artery disease (age >45 years, diabetes, tobacco, or drug use), but the yield is often low. The aim of this study was to evaluate the importance of estimated donor 10-year atherosclerotic cardiovascular disease (ASCVD) risk (≤5% vs >5%) vs coronary angiogram testing for predicting short- to mid-term survival free from graft failure in adult heart transplant recipients. METHODS: Adult heart transplant recipients from the United Network for Organ Sharing database 18 October 2018, to 31 December 2023, who received hearts from donors aged >40 years, or >30 years with diabetes, hypertension, or smoking were included. The risk of a composite outcome (death or graft failure) up to 4 years post-transplant was assessed by multivariable Cox regression. RESULTS: Of 5152 recipients, 86.1% received hearts from donors with ASCVD risk ≤5%. Angiography was performed in 76.1% donors with ASCVD ≤5% and 92.9% of donors with ASCVD >5%. Using donors with ASCVD ≤5% and angiography as the reference group (n = 3378), adjusted hazard ratios for the composite outcome were .91 [95% confidence interval (CI) .74-1.11] for ASCVD ≤5% without angiography (n = 1060); 1.30 (95% CI 1.05-1.60) for ASCVD >5% with angiography (n = 663), and .88 (95% CI .36-2.13) for ASCVD >5% without angiography (n = 51). Findings were consistent when limited to donors meeting current angiography guideline criteria. CONCLUSIONS: Estimated ASCVD risk >5% independently predicts worse transplant outcomes, while routine coronary angiography in low-risk donors (ASCVD ≤5%) does not. These findings suggest that ASCVD-based risk stratification may be more useful than angiography as the initial step in donor heart selection.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Gnesin F, Mehra MR, Thomalla J, et al. Heart transplantation allograft survival: donor atherosclerotic disease risk vs coronary angiography. Eur Heart J. 2026. PMID: 42619250. doi:10.1093/eurheartj/ehag488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。